权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses

基于血清学抗体分析的 SARS-CoV-2 感染对肺癌的脆弱性

基本信息

批准号：
10706729
负责人：
Adolfo Garcia-Sastre
金额：
$ 12.01万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-30 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10706729
关键词：
2019-nCoV ACE2 Adult Advocate Age Aggressive course Antibodies Antibody Response Bioinformatics Biology Biometry Budgets COVID-19 COVID-19 mortality COVID-19 patient COVID-19 susceptibility COVID-19 vaccination COVID-19 vaccine Cancer Patient Cardiopulmonary Cells Characteristics Clinical Clinical Sciences Clinical Trials Complement Contracts Control Groups Cytoprotection Data Science Data Science Core Demographic Factors Development Disease Doctor of Philosophy Epithelial Cells Ethnic Origin Fatality rate Gender Histology Immune Immune response Incidence Individual Infection Informatics Kinetics Knowledge Longevity Lung Lung Neoplasms Malignant Neoplasms Malignant neoplasm of lung Mediating Morbidity - disease rate Normal tissue morphology Patient Recruitments Patients Persons Play Population Control Predisposition Race Recording of previous events Research Risk Factors Role SARS-CoV-2 antibody SARS-CoV-2 infection Science Serology Seroprevalences Smoking Smoking History Tobacco Vaccination Vaccines Viral Viral Load result Virus Virus Diseases Virus Replication base cancer therapy cigarette smoking comorbidity data dissemination human subject inter-individual variation lung cancer cell member multidisciplinary neoplastic cell neutralizing antibody patient population programs protective efficacy public database response sample collection tumor vaccine trial

项目摘要

As a supplement to our existing U54, we propose that Mount Sinai serve as a coordinating site for aggregating and analyzing demographic, clinical and molecular data from multiple lung cancer studies supported by SeroNet. These studies, from prominent institutions across the country, have been investigating the intersection of lung cancer and SARS-CoV-2 to explore the impact of the combined diseases on patient health, investigate the underlying biology that leads to poor outcomes and understand the effects of lung cancer disease and/or treatments on SARS-CoV-2 vaccination-induced immune responses. To accomplish this goal, we will leverage the considerable expertise and experience of the Mount Sinai Bio-informatics group, led by Joseph Finkelstein, and the data analysis capabilities of our partners at the Vanderbilt Department of Statistics.

作为我们现有U 54的补充，我们建议西奈山作为一个协调站点，用于汇总和分析来自SeroNet支持的多项肺癌研究的人口统计学、临床和分子数据。这些研究来自全国各地的著名机构，一直在调查肺癌和SARS-CoV-2的交叉点，以探索合并疾病对患者健康的影响，调查导致不良结果的潜在生物学，并了解肺癌疾病和/或治疗对SARS-CoV-2疫苗诱导的免疫反应的影响。为了实现这一目标，我们将利用约瑟夫·芬克尔斯坦领导的西奈山生物信息学小组的大量专业知识和经验，以及我们在范德比尔特统计部的合作伙伴的数据分析能力。